Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.
B cells
NSCLC
PD-L1 blockade
RNA-seq
TLS
atezolizumab
immunotherapy
plasma cells
randomized clinical trials
tertiary lymphoid structures
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
14 03 2022
14 03 2022
Historique:
received:
26
01
2021
revised:
11
11
2021
accepted:
02
02
2022
pubmed:
27
2
2022
medline:
3
5
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) benefit. Using transcriptomic analysis of 891 NSCLC tumors from patients treated with either the PD-L1 inhibitor atezolizumab or chemotherapy from two large randomized clinical trials, we find a significant B cell association with extended OS with PD-L1 blockade, independent of CD8
Identifiants
pubmed: 35216676
pii: S1535-6108(22)00035-6
doi: 10.1016/j.ccell.2022.02.002
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
289-300.e4Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests All authors are employees and stockholders of Genentech/Roche. N.S.P., B.Y.N., S.M., and R.B. are co-inventors on a provisional patent application filed by Genentech/Roche relating to this manuscript.